A5082834225- Pulmonary Hypertension Research and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Obstructive Sleep Apnea Research
- Vascular Anomalies and Treatments
- Tracheal and airway disorders
- Neuroscience of respiration and sleep
- Heart Failure Treatment and Management
- Congenital Heart Disease Studies
- Neonatal Respiratory Health Research
- Nosocomial Infections in ICU
- Trace Elements in Health
- Congenital Diaphragmatic Hernia Studies
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Cardiovascular Issues in Pregnancy
- Hemodynamic Monitoring and Therapy
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Bone and Joint Diseases
- Sepsis Diagnosis and Treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Systemic Sclerosis and Related Diseases
- Peptidase Inhibition and Analysis
- Pneumocystis jirovecii pneumonia detection and treatment
- Neuroendocrine Tumor Research Advances
University of Arizona
2023-2025
Banner - University Medical Center Phoenix
2025
University of Nebraska Medical Center
2021-2024
Lung Institute
2024
University of Michigan
2022-2023
Nebraska Medical Center
2023
University of Louisville
2013-2022
Wilmington University
2022
Acceleron Pharma (United States)
2022
University of Louisville Hospital
2013-2021
Background Inhaled treprostinil (iTre) is the only treatment approved for pulmonary hypertension due to interstitial lung disease (PH-ILD) improve exercise capacity. This post hoc analysis evaluated clinical worsening and PH-ILD exacerbations from 16-week INCREASE study change in 6-minute walking distance (6MWD) open-label extension (OLE) patients with less severe haemodynamics. Methods Patients were stratified by baseline vascular resistance (PVR) of <4 Wood units (WU) versus ≥4 WU ≤5...
Pulmonary arterial hypertension (PAH) prevalence is increasing worldwide, and the prognosis poor with 5-year survival < 50% in high risk patients. The relationship between metal exposure/essential dyshomeostasis PAH/right ventricular dysfunction less investigated. aim of this study to investigate vegetable consumptions levels PAH patients controls. This was a prospective, single center pilot study. Questionnaires were completed by all subjects (20 10 healthy controls) on smoking, exposure...
Pulmonary hypertension due to interstitial lung disease (ILD-PH) portends very poor clinical outcomes, with a median survival time of 1.5 2 years. Currently, there is no tool assess the risk worsening in patients ILD-PH. Our aim was derive simple and practical calculator that could be used predict The INCREASE study 16-week evaluated inhaled treprostinil Baseline data from who were randomized placebo arm (n=163) thus untreated any approved pulmonary artery vasodilators calculator. endpoint...
Background Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by persistent clot burden and secondary vascular remodeling. Pulmonary thromboendarterectomy (PTE) remains the preferred curative treatment for CTEPH. This study presents a descriptive analysis of surgical outcomes in patients undergoing PTE CTEPH at tertiary referral hospital. Methods From 2015 to 2023, 40 underwent PTE. Data on perioperative postoperative were retrospectively collected. Continuous variables...
Partial anomalous pulmonary venous return (PAPVR) is a rare congenital anomaly that results in left-to-right shunt. Based on the shunt fraction, PAPVR has wide spectrum of presentations. If significant left unrepaired, vascular remodeling can occur resulting development arterial hypertension (PAH). Furthermore, if condition associated with an atrial septal defect (ASD), patient develop reversal and Eisenmenger's syndrome setting severe PAH. Management plans include close observation,...
Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and associated with interstitial lung disease in the United States. Studies have confirmed robust benefits safety of nebulized inhaled treprostinil, but it requires a time investment nebulizer preparation, maintenance, treatment. A small, portable dry powder inhaler has been developed treatment PAH. The primary objective this study was to evaluate tolerability inhalation (TreT) patients currently treated...
Ischaemic papillary muscle rupture causing acute severe mitral regurgitation (MR) has a dramatic presentation and very high mortality. Emergent surgical repair improves outcomes, which necessitates robust preoperative stabilisation. Here we discuss patient with cardiogenic shock an MR that was deemed risk for emergent valve replacement due to haemodynamic instability respiratory failure. A percutaneous left ventricular assist device Impella 2.5 (Abiomed, Danvers, MA) drastically improved...
Abstract Social determinants of health (SDoH) can impact the vulnerable pulmonary arterial hypertension (PAH) population, especially during COVID‐19 pandemic. Providers' understanding SDoH at point care and their is unknown. We conducted semi‐structured virtual interviews with US clinicians 17 (PH) centers one patient advocate from Pulmonary Hypertension Association. sought participants' perspective on in PAH impact. Transcripts were developed analyzed for key themes to assess potential...
This study aimed to examine the effect of sleep state (rapid eye movement [REM] versus non-rapid [NREM]) and position (supine non-supine position) on obstructive respiratory events distribution in adolescent population (ages 12 18 y).This was a retrospective that included 150 subjects between ages y with an apnea-hypopnea index (AHI) > 1/h. Subjects using REM sleep-suppressant medications history genetic anomalies or craniofacial syndromes were excluded.The median age 14 interquartile range...
Disseminated histoplasmosis can occur in immunocompromised patients such as HIV disease and with medication-induced immunosuppression. Most of these present fever, weight loss, hepatosplenomegaly, lymphadenopathy, pancytopenia. There are increasing reports coronavirus 2019 (COVID-19) pneumonia associated fungal infections including aspergillus mucormycosis. It is not typical for immunocompetent to disseminated disease. We herein report a case 50-year-old male recent recovery from COVID-19...
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pressure in the pulmonary arteries, commonly resulting right heart failure. PAH associated with high economic burden throughout duration of disease. This retrospective cohort study Milliman Contributor Health Source Data, Medicare 100% Research Identifiable Files, and Merative Marketscan® Commercial dataset between 2018 2020 identified adult patients prevalent based on earliest qualifying diagnosis date...
It is unknown if environmental antimony exposure influences pulmonary arterial hypertension (PAH) and right ventricular function. We performed a pilot study to evaluate levels in 20 PAH patients 10 controls. Also, we explored the correlation of level with prognostic hemodynamic markers. Antimony blood plasma were significantly higher when compared controls [blood: mean ± SD (95%CI) 1.3 0.6 (1.0-1.5) ng/ml vs. control (95%) 0.7 0.5 (0.4-1.0) ng/ml, p = 0.017] [plasma: PH 2.6 1 (2.2-3.1) 1.5...
Abstract Treatment for pulmonary arterial hypertension (PAH) has evolved over the past decade, including approval of new medications and growing evidence to support earlier use combination therapy. Despite these changes, few studies have assessed real‐world treatment patterns, healthcare resource utilization (HCRU), costs among people with PAH using recent data. We conducted a retrospective cohort study administrative claims from HealthCore Integrated Research Database®. Adult members...